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COVID-19 AND ITS IMPACT(S) ON INNOVATION
Clark D. Asay* and Stephanie Plamondon Bair**
In previous work, we explored how certain characteristics of
adversity are often more conducive to innovation than others. In this
Article, prepared as part of the Lee E. Teitelbaum Utah Law Review
Symposium—The Law & Ethics of Medical Research, we review some of
that work and apply it specifically to the COVID-19 context. We conclude
by assessing certain policy implications in light of how the COVID-19
pandemic has both spurred and hindered innovation.
INTRODUCTION
Sometimes adversity hinders innovation, but sometimes it promotes it. In other
work,1 we draw on various literatures to identify which characteristics of adversity
are most conducive to innovation and which are most likely to stifle it. That work
suggests that for adversity to have the best chance of promoting innovation, it should
satisfy the Goldilocks principle: the adversity should be neither too much nor too
little, neither too intense nor too temperate, neither too pervasive nor too narrow, but
“just right.” Furthermore, adversity collectively experienced, with severe
consequences if left unaddressed, is also more likely to trigger innovation. But again,
if the consequences are too severe or the adversity impacts too many in a community,
those characteristics may hinder innovative responses.
Of course, these principles are not ironclad. Many people and organizations
innovate despite the adverse conditions they face being less than ideal, while many
parties fail to innovate despite being confronted with adverse conditions conducive
to innovative activity. In other words, individual and organizational characteristics
also matter in terms of whether a party responds to adversity with innovation. But
overall, based on the existing literatures, adversity that satisfies these principles
stands a better chance of promoting innovation, all else being equal.
In this Article, we review some of our findings on adversity and innovation and
apply them specifically to the COVID-19 context. The COVID-19 case study offers
a number of examples of how adversity may either inhibit or promote innovation,
depending on its characteristics, and this Article explores some of these examples.
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1
See generally Clark D. Asay & Stephanie Plamondon Bair, Innovation in Adversity,
49 FLA. ST. U. L. REV. (forthcoming), https://dx.doi.org/10.2139/ssrn.3801184
[https://perma.cc/8S2W-9X45] (presenting the theory of innovation applied in this Article).
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We first review some of the key takeaways from our separate work. For each
of these takeaways, we then examine examples in the COVID-19 context that
illustrate these principles at play. Finally, we consider some possible policy
implications that follow from adversity’s role in both promoting and inhibiting
innovative efforts during the COVID-19 pandemic.
I. ADVERSITY’S RELATIONSHIP TO INNOVATION AND THE COVID-19 PANDEMIC
Adversity, broadly defined, can be both a conduit and a roadblock to
innovation.2 But what are the clues as to which role adversity will play in any given
instance? In our other work, we drew on research from diverse literatures to identify
four features of adversity that can affect an organization or individual’s capacity to
innovate: the discreteness of the adversity across both spatial and temporal domains,
the intensity of the adversity, how widely the adversity is experienced, and the
potentially harmful consequences of the adversity if left unaddressed.3
In this Part, we briefly review these findings and then analyze how they apply
to the COVID-19 pandemic and the innovation (or lack thereof) that has taken place
in response to it. Specifically, we examine the extent to which features we previously
identified as relevant to innovation in adversity have been present in the COVID-19
context and how those features may have affected the course of innovation.
A. The Goldilocks Principle
In our other research, we identified a so-called Goldilocks relationship between
four features of adversity and the likelihood that parties will respond to adversity
with innovation.4 According to this relationship, adversity should fall within a
favorable range of temporal and spatial discreteness, intensity, collectiveness, and
consequences to have the best chance of stimulating innovative responses.5
The Goldilocks principle can be understood in terms of a balancing of
motivation and resources. On the one hand, adversity tends to provide strong
incentives for individuals and organizations to innovate.6 The challenges adversity
presents naturally invite innovative responses, as individuals react to adversity with
2
See Asay & Plamondon Bair, supra note 1, at 9–10. In this work, we defined adversity
broadly to include any event or set of circumstances, major or minor, that challenged an
individual or organization in pursuit of their goals. Adversity could occur at the individual
level, as in instances of illness or job loss; at the organizational level, as with financial or
human resources challenges; or at the societal level, like with natural disasters or the COVID19 pandemic. Id. at 9–12.
3
Id. at 12.
4
Id. at 6.
5
Id. at 6–7.
6
See, e.g., Bhaskar Chakraorti, Finding Competitive Advantage in Adversity, HARV.
BUS. REV. (Nov. 2010), https://hbr.org/2010/11/finding-competitive-advantage-in-adversity
[https://perma.cc/PVH6-9GN5] (discussing entrepreneurs using adversity as a competitive
advantage in innovation).
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creativity as a means of overcoming their challenges7 or simply as an emotional
coping mechanism.8 On the other hand, however, creativity and innovation tend to
be resource-intensive endeavors.9 They often require time, money, cognitive power,
and emotional and social support to succeed. Ideally, then, adversity should be
significant enough in a particular domain to provide the necessary motivation to
innovate without being so significant that it drains the very resources necessary to
do so.
For example, a party is unlikely to respond to adversity with innovation if the
adversity is spatially and temporally unbounded. Take long-term poverty, which can
work to prevent many of those experiencing it from responding to their
circumstances with innovation.10 This is so in part because the adversity is
overwhelming across both temporal and spatial domains. On the temporal front, the
long-term nature of their impoverished state tends to sap the suffering individuals’
motivation to innovate and monopolizes the mental and economic resources
necessary for innovation. On the spatial front, poverty tends to drain a person’s
cognitive, financial, and emotional assets by making constant demands in every
facet of their life, thus further eroding their ability to think and act creatively in
response to their adverse life circumstances.11
On the other hand, adversity that is too fleeting in time or narrow across an
individual’s life or an organization’s operational domains is less likely to spur
innovation. For instance, parties that experience a brief bout of adversity may often
fail to respond to it with innovation because it has come and gone so quickly that the
motivational nudge never materializes. Instead, an innovative response is more
likely when a party experiences adversity that demands action in part because the
adversity lingers (at least long enough to inspire a creative response). Adversity that
is too narrow in scope is similarly unlikely to trigger a creative response because
that adversity is sufficiently confined in a party’s life or operations that the adversity
may hardly register. Even if it does register, it is simply too limited in scope to
motivate an innovative response.
The same principles hold for the intensity of a challenge. Adversity that is too
intense often precludes innovative responses to that adversity for the same reasons
temporally and spatially unbounded adversity are innovation killers: the adversity’s
high intensity monopolizes a party’s motivation and resources such that innovation
7

Id.
Mark A. Runco, Tension, Adaptability, and Creativity, in THE SERIES IN CLINICAL
AND COMMUNITY PSYCHOLOGY: AFFECT, CREATIVE EXPERIENCE, AND PSYCHOLOGICAL
ADJUSTMENT 165, 167 (Sandra W. Russ ed., 1999).
9
Glenda Claire Jones, An Exploration of Experiences and Expression of Artistic
Creativity During Adversity and Resilient Recovery 291–93 (May 2013) (Ph.D. dissertation,
Saybrook University) (ProQuest).
10
Stephanie Plamondon Bair, Impoverished IP, 81 OHIO ST. L.J. 523, 554–56 (2020).
11
See Cara Feinberg, The Science of Scarcity: A Behavioral Economist’s Fresh
Perspectives on Poverty, HAR. MAG. (May-June 2015), https://harvardmagazine.com/2015/
05/the-science-of-scarcity [https://perma.cc/U4EK-QMNM] (providing an overview of
economist Sendhil Mullainathan’s work on the impact of scarcity on economic behavior).
8
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is either extremely difficult or simply out of the question. Conversely, when
adversity is not intense enough, it can fail to stimulate innovative responses, in part
because parties deem that the adversity’s low intensity does not merit a response.
Another feature of adversity that affects its relationship to innovation is whether
the adversity is experienced collectively or in isolation. When adversity is
experienced collectively, it is more likely to trigger innovative responses than when
it is experienced in isolation. This is so because shared adverse experiences tend to
increase feelings of relatedness and interpersonal support,12 and a significant body
of research shows that when people feel related to and supported by those around
them, they tend to be more productive and motivated in ways conducive to creativity,
including the ability to generate novel ideas.13 Conversely, when parties experience
adversity in isolation, that adversity is less likely to trigger successful innovation.
Unlike parties experiencing adversity in common, the isolated party often lacks the
support structures in their life or operations necessary to innovate effectively.14
Adversity experienced collectively is also more likely to trigger innovation
when the consequences of failing to do so are severe. History is full of examples of
governments and organizations responding to the challenges presented by various
severe threats to society with impressive and groundbreaking innovation.15
Conversely, when adversity falls short of posing dire consequences if left
unaddressed, those impacted are less likely to respond to it with innovative solutions.
This principle is related to the discussion above about adversity intensity: when
parties judge that the consequences of leaving adverse conditions unaddressed are
not dire enough, they may simply lack the motivation to respond to the adversity
with innovation.16 This may be particularly so when other concerns demand
society’s collective energy.
But consistent with the Goldilocks principle, when adverse conditions are too
commonly shared or their consequences are simply overwhelming, those conditions
may hinder successful innovative responses. For instance, if an entire community is
impoverished, that adversity poses significant obstacles to innovation because the
entire community may lack the resources necessary to innovate its way out of those
hardships, despite the fact that the shared adversity might otherwise create feelings
of connectedness.
Again, we wish to emphasize that a particular party’s individual characteristics
certainly play a role in whether that party responds to adversity with innovation. In
12

Indeed, much research shows that a variety of adverse experiences, including natural
disasters, can often increase a community’s bonds and result in mutual support for members
within the community. See, e.g., Lisa Grow Sun, Disaster Mythology and the Law, 96
CORNELL L. REV. 1131, 1138 (2011) (reviewing some of this literature).
13
See Asay & Plamondon Bair, supra note 1, at 24-26 (reviewing some of the
literature).
14
Id. at 26–27.
15
See id. at 28–29 (discussing the examples of satellite, GPS, internet, and nuclear
weapons technologies, all of which arose at least in part due to perceived severe threats to
the interests of particular governments or societies).
16
See discussion infra Section I.C.
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other words, whether some party responds to adversity with innovation is not always
determined by whether the adversity is conducive to innovation. For instance, we all
know inspiring stories of individuals and organizations that have overcome long
odds with their creativity and ingenuity.17 And this may be so even when the
adversity is excessively intense, spatially unbounded, of extreme duration, or is
experienced in isolation. On the other hand, we may also know stories of parties
facing “just right” amounts of adversity that have nevertheless fallen short in
responding with creativity. Be that all as it may, the characteristics of the adversity
that a party faces appear to affect the likelihood that the party will respond to the
adversity with innovative responses, all else being equal.
B. The Goldilocks Principle: Examples of COVID-19’s Impact on Innovation
We have seen many examples of the COVID-19 pandemic as both a stimulant
and hindrance to innovation. In this Section, we review several examples of the
Goldilocks principle at play.
1. Suboptimal Intensity and Scope
Perhaps the most obvious example of COVID-19 failing to satisfy the
Goldilocks principle and thereby stymieing innovation is when the disease proves
fatal. Millions of people across the globe have succumbed to this awful disease, and
those lives represent significant lost sources of innovation.18 In such cases, the
Goldilocks principle is clearly unsatisfied because the adversity’s intensity is so
great and unbounded that those affected are literally unable to survive, let alone
engage in innovation.
Even many who have survived or have not been infected with the virus are
enduring significant impacts that in many cases may make it more difficult for them
to engage in creative endeavors. For example, the obstacles in dealing with one’s

17

See, e.g., Renee Jacques, 16 Wildly Successful People Who Overcame Huge
Obstacles to Get There, HUFFPOST (Dec. 16, 2017), https://www.huffpost.com/entry/succ
essful-people-obstacles_n_3964459 [https://perma.cc/JN9D-ASNS].
18
See, e.g., Gabe Friedman, Those We Lost in 2020: Remember the Rabbis, Pioneers,
Innovators, and Family Members, Obituaries, JEWISH TELEGRAPHIC AGENCY (Dec. 28,
2020, 11:46 AM), https://www.jta.org/2020/12/28/obituaries/those-we-lost-in-2020remembering-the-rabbis-pioneers-innovators-and-family-members [https://perma.cc/T5C6FN2N]; Those We’ve Lost, N.Y. TIMES (Feb. 13, 2021), https://www.nytimes.com/interact
ive/2020/obituaries/people-died-coronavirus-obituaries.html
[https://perma.cc/H33DJB5N]; Faces of the Dead, WASH. POST (July 31, 2020), https://www.washingtonpost.com/
health/2020/04/24/coronavirus-dead-victims-stories/?arc404=true#DeLeon [https://perma.
cc/A9F7-E3TZ].
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own or a loved one’s illness,19 the loss of typical routines,20 the financial challenges
associated with job losses that many have experienced during the pandemic,21 and
the loss of emotional and social support systems due to social distancing, alone or
combined in individual cases, are often significant enough to drain the motivation
and resources necessary to innovate.22
There is reason to believe that those who are already struggling with various
forms of adversity in their lives are also the most likely to be affected in severe ways
by the COVID pandemic.23 For these populations, including those struggling with
financial challenges, racial bias, mental health challenges, and lack of access to
medical services, the challenges presented by the COVID pandemic are often the
“straw that breaks the camel’s back” in terms of pushing them out of the ideal range
of innovation-promoting adversity.24 This is concerning in part because there is
already significant evidence that these populations are innovating at lower levels

19

Grief and Loss, CTRS. FOR DISEASE CONTROL AND PREVENTION (June 11, 2020),
https://www.cdc.gov/coronavirus/2019-ncov/daily-life-coping/stress-coping/grief-loss.html
[https://perma.cc/NTF2-GW68] (providing resources for coping with grief stemming from
COVID-19, particularly with respect to the loss of loved ones).
20
Coronavirus Grief: Coping with the Loss of Routine During the Pandemic, MAYO
CLINIC (Oct. 13, 2020), https://www.mayoclinic.org/diseases-conditions/coronavirus/indepth/coping-with-coronavirus-grief/art-20486392
[https://perma.cc/56ZR-76EE]
(discussing how loss in routine stemming from COVID-19 can result in grief and listing
coping mechanisms for dealing with that grief).
21
Kim Parker, Rachel Minkin & Jesse Bennett, Economic Fallout from COVID-19
Continues to Hit Lower-Income Americans the Hardest, PEW RESEARCH CENTER (Sept. 24,
2020),
https://www.pewsocialtrends.org/2020/09/24/economic-fallout-from-covid-19continues-to-hit-lower-income-americans-the-hardest/
[https://perma.cc/CJA3-SWER]
(discussing the significant financial strains COVID-19 has caused in American society,
particularly with respect to low-income individuals).
22
Catriona R. Mayland, Andrew J.E. Harding, Nancy Preston & Sheila Payne,
Supporting Adults Bereaved Through COVID-19: A Rapid Review of the Impact of Previous
Pandemics on Grief and Bereavement, 60 J. PAIN SYMPTOM MGMT. e33, e33 (2020)
(“Owing to social isolating measures and lack of usual support structures, [COVID-19] also
is likely to influence experiences of grief and mourning.”).
23
See, e.g., Cong S. Pham & Devashish Mitra, The Color of Coronavirus (Dec. 31,
2020) (unpublished manuscript) https://ssrn.com/abstract=3757854 [https://perma.cc/8WFK
-XMM4] (summarizing in the Abstract that the paper finds “robust evidence that the COVID19 death ratio and infection ratio are positively associated with income inequality, higher
non-White/White residential segregation index, and higher percentage of adults aged 65 and
below without health insurance”).
24
Indeed, many have pointed to the negative mental health effects of prolonged
isolation as possibly more damaging than the actual virus itself. See, e.g., Jennifer Rigby, Is
the Cure Worse than the Disease? The Hidden Harms of the COVID-19 Lockdowns,
TELEGRAPH (June 5, 2020, 12:00 PM), https://www.telegraph.co.uk/global-health/scienceand-disease/cure-worse-disease-hidden-harms-covid-19-lockdowns/ [https://perma.cc/9FV
4-67WS].
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than one might expect.25 The distributional effects of COVID-19, considered in
conjunction with the Goldilocks principle, may mean that society will see even lower
levels of innovation from these groups in the short term, as they attempt to deal
individually and in their communities with the fallout from the pandemic.
Some of the same holds true with respect to organizations. For instance,
lockdown measures taken in response to the pandemic have created adverse
conditions that are simply too intense, enduring, and all-encompassing for many
parties to effectively cope with, let alone innovate their way out of. We have all
heard stories of many restaurants necessarily shuttering their operations for lack of
customers, and the mounting empirical evidence about COVID-19’s impact on the
restaurant industry looks grim.26 While some restaurants were able to respond to the
pandemic with innovation,27 many others were likely too overwhelmed by the
challenges precipitated by it to do so. Other small enterprises without the resources
to effectively weather the COVID-19 storm have similarly suffered.28 Even once
thriving, large companies have succumbed to the adverse conditions that the
pandemic has brought.29 For many of these parties, the pandemic may have been the
final straw that transformed the challenges they faced from possible innovation
promoters to certain innovation killers.
Further, in addition to the cognitive impacts that severe adversity itself
imposes,30 there is increasing evidence that COVID-19 may have an even more
direct effect on the ability of those infected with the virus to innovate due to the
impacts of the virus on patients’ brains. Reports from the medical community range
25

Plamondon Bair, supra note 10, at 554–56 (discussing the research demonstrating
that members of poor and minority populations innovate at lower levels than those from more
privileged populations).
26
Colman Andrews, Restaurants Closing: 35 of the Most Popular that Won’t Reopen
After the Coronavirus Pandemic, USA TODAY (Aug. 13, 2020, 7:00 AM ET),
https://www.usatoday.com/story/money/2020/08/13/the-35-most-popular-restaurants-thatwont-reopen-after-the-pandemic/42198639/ [https://perma.cc/C6VG-4CQT] (reviewing the
pandemic’s negative impacts on the restaurant industry, including the permanent closing of
57,000 restaurants).
27
See, e.g., Eve Turow-Paul, How Restaurants Are Innovating During the COVID-19
Pandemic, FORBES (Mar. 23, 2020, 9:00 AM EDT), https://www.forbes.com/sites/eveturow
paul/2020/03/22/how-restaurants-innovating-during-the-covid-19-pandemic/?sh=6cb59daf
2c2b [https://perma.cc/JDB5-UD5K].
28
See Alexander W. Bartik, Marianne Bertrand, Zoe Cullen, Edward L. Glaeser,
Michael Luca & Christopher Stanton, The Impact of COVID-19 on Small Business Outcomes
and Expectations, 117 PNAS 17656 (2020) (reviewing growing evidence of negative effects
on small enterprises and their financial fragility).
29
See Hank Tucker, Coronavirus Bankruptcy Tracker: These Major Companies Are
Failing Amid the Shutdown, FORBES (Nov. 10, 2020, 3:00 PM EDT),
https://www.forbes.com/sites/hanktucker/2020/05/03/coronavirus-bankruptcy-tracker-these
-major-companies-are-failing-amid-the-shutdown/?sh=1d9448ce3425 [https://perma.cc/HV
3T-7APN] (listing a number of major companies that have filed for bankruptcy during the
pandemic).
30
See Asay & Plamondon Bair, supra note 1, at 14–15.
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from relatively common and minor neurological symptoms arising from an infection
like the loss of taste or smell31 to more concerning outcomes like long-lasting brain
fog,32 the possibility of cognitive decline after recovery,33 and even psychosis in a
small number of cases.34 Even when cognitive capacity otherwise remains intact,
some victims of COVID-19, so-called “long haulers,” appear to suffer from a range
of other long-term adverse effects, including extreme fatigue, and these effects may
similarly inhibit innovative responses now and in the future.35 Although it will be
quite some time before the cognitive and other long-term effects of COVID-19 are
fully understood, these preliminary reports suggest that the pandemic will have long
term consequences for the collective potential of society to engage in innovative
endeavors due to the significant drain on resources it has imposed on millions of
people.36
Finally, another direct and severe effect of the pandemic on society’s innovative
potential may arise from the widespread disruption to education that has resulted
from the closure of schools in response to the risk of infection. This adversity, which

31

See, e.g., Xiangliang Chen, Sarah Laurent, Oezguer A. Onur, Nina N. Kleineberg,
Gereon R. Fink, Finja Schweitzer & Clemens Warnke, A Systematic Review of Neurological
Symptoms and Complications of COVID-19, 268 J. NEUROLOGY 392, 399 (2021).
32
See, e.g., Masoud Mardani, Editorial, Post COVID Syndrome, 15 ARCHIVES
CLINICAL INFECTIOUS DISEASE e108819 (Sept. 13, 2020), https://sites.kowsarpub.com/arch
cid/articles/108819.html [https://perma.cc/MZK5-73QM].
33
See, e.g., Carrie Arnold, The Link Between Delirium and Dementia, 588 NATURE 22
(2020) (reporting on research exploring the relationship between the common COVID-19
symptom of delirium and an increased risk for dementia and cognitive decline); Gabriel A.
de Erausquin, Heather Snyder, María Carrillo, Akram A. Hosseini, Traolach S. Brugha &
Sudha Seshadri, The Chronic Neuropsychiatric Sequelae of COVID 19: The Need for a
Prospective Study of Viral Impact on Brain Functioning, Alzheimer’s & Dementia, J.
ALZHEIMER’S ASS’N (Sept. 16, 2020) (proposing a research agenda to study the “key
questions on the impact [of COVID-19] for risk of later life cognitive decline, AD, and other
dementia”).
34
See, e.g., Andrew Joseph, When Covid-19 Hits the Brain, It Can Cause Strokes,
Psychosis, and Dementia-like Syndrome, New Survey Shows, STAT (June 25, 2020),
https://www.statnews.com/2020/06/25/covid-19-brain-complications/ [https://perma.cc/9C
S5-2S5P] (reporting the results of a survey of 125 hospitalized patients with COVID-19 and
neurological complications, and finding that ten of those patients were newly diagnosed with
psychosis).
35
Sandi Dougton, Many of the Earliest COVID ‘Long-Haulers’ Still Suffer; Seattle
Researchers Are Trying to Figure Out Why, SEATTLE TIMES (Jan. 25, 2021, 7:58 AM),
https://www.seattletimes.com/seattle-news/health/nearly-a-year-on-many-of-the-earliestcovid-19-long-haulers-are-still-not-back-to-normal/
[https://perma.cc/X8RV-CDDD]
(discussing other long-term effects for some COVID-19 victims, including extreme fatigue).
36
In fact, one study, which has not yet completed the peer review process, suggests that
infection with COVID-19 may age the brain up to ten years and result in an IQ drop of up to
8.5 points in some patients. Carolyn Crist, Study Shows COVID-19 May Cause Brain Aging,
WEBMD (Oct. 29, 2020), https://www.webmd.com/lung/news/20201028/study-showscovid-19-may-cause-brain-aging [https://perma.cc/NZ7P-PNTA].
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has been severe for many,37 has not only potentially reduced the current ability of
students at all levels to innovate in classrooms and laboratories but may also have
long-term negative consequences for societal innovation as important
developmental windows for learning pass without appropriate education taking
place.38 As with the other forms of adversity introduced by COVID-19, there is
increasing concern that these impacts will disproportionately impact alreadyvulnerable populations, thereby further increasing the likelihood that the Goldilocks
principle will not be satisfied for these groups either in the short or long term and
resulting in even lower levels of innovation from these groups.39
2. “Just Right” Intensity and Scope
On the flip side, one can also observe examples of the Goldilocks principle for
intensity and scope being satisfied during COVID-19. For each person who has been
significantly impacted by the pandemic, there are a number of people and
organizations for whom the adversity appears to have been less severe and, in fact,
has fallen in that sweet spot of duration, breadth, and intensity conducive to
innovation.40 For these people and organizations, the pandemic may have provided
the appropriate motivation to engage in creative and innovative activities.
Indeed, society has experienced a surge in COVID-related innovation in
response to the challenges the disease poses. Examples include the development of
new types of protective gear and medical equipment, novel approaches to business
operations, and even legal innovations designed to facilitate COVID-related

37
See, e.g., Adverse Consequences of School Closures, UNESCO,
https://en.unesco.org/covid19/educationresponse/consequences
[https://perma.cc/H6G2MZCN] (last visited Feb. 9, 2021) (listing some of the significant impacts of school closures
on individuals, families, and communities, including social isolation, reduced access to
healthcare, increased vulnerability of children to exploitation, decreased ability for
caregivers to work due to childcare challenges and provide financially for their families).
38
See, e.g., Bruno V. Manno, The Awful Economic Impact of School Closings,
REALCLEAR EDUC. (Oct. 9, 2020), https://www.realcleareducation.com/articles/2020/10/09
/the_awful_economic_impact_of_school_closings_110485.html [https://perma.cc/2VNQPL5E] (citing an Organization for Economic Cooperation and Development (OECD) report
estimating that the loss of learning and reduced individual skill level attributable to COVIDrelated school closures will result in a 1.5% loss of the U.S.’s future Gross Domestic Product,
which represents a loss of 14.2 trillion 2020 U.S. dollars over the next 80 years).
39
See, e.g., Adverse Consequences of School Closures, supra note 37 (noting that the
negative impact of school closures “is particularly severe for the most vulnerable and
marginalized boys and girls and their families . . . exacerbat[ing] already existing disparities
within the education system but also in other aspects of their lives”).
40
One survey of academic researchers, for example, found that the majority of
researchers surveyed had not experienced any significant disruptions to their daily work and
had been able to continue with most of their professional duties. Chantelle Rijs & Frederick
Fenter, FRONTIERS PUB. HEALTH, The Academic Response to COVID-19, 5–6 (Oct. 28,
2020), https://doi.org/10.3389/fpubh.2020.621563 [https://perma.cc/33SQ-RSYG].
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research.41 Perhaps the most striking example of innovation in response to the
pandemic is the research that has led to the development of a number of effective
COVID vaccines on a timeline unprecedented for modern vaccine development.42
This innovative response to the adversity imposed by COVID has not gone
unnoticed, with a number of commentators discussing the ways in which the COVID
pandemic has motivated and mobilized innovative communities.43
In the context of the vaccine developments in particular, we can see aspects of
the Goldilocks principle in play. For instance, the disease has proved deadly enough
to inspire action in the form of vaccine development, but not so deadly as to make
responding to it practically impossible.44 Furthermore, though the disease presents
significant obstacles for individuals and organizations alike, those involved in
creating the vaccines have found ways to collaborate and engage in unprecedented
amounts of information sharing on their way to the development of several
successful COVID-19 vaccines.45 Hence, the disease’s middling intensity and
relative spatial discreteness (at least for some) have made it in some ways an ideal
candidate for innovative solutions, though that is cold comfort for those that have
suffered from it. Finally, even early on in the pandemic, promising signs emerged
that the disease need not be an enduring plague, though many questions about the
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Asay & Plamondon Bair, supra note 1, at 2–3.
See, e.g., Philip Ball, The Lightning-Fast Quest for COVID Vaccines––and What It
Means for Other Diseases, 589 NATURE 16, 16 (2021) (discussing how the speedy rate of
vaccine development in response to COVID has revolutionized the field by “challeng[ing]
our whole paradigm of what is possible in vaccine development”) (quoting Natalie Dean,
Biostatistician at the University of Florida in Gainesville).
43
See, e.g., Goda Naujokaitytė, COVID-19 Triggered Unprecedented Collaboration in
Research, SCI. BUS. (Jan. 12, 2021), https://sciencebusiness.net/covid-19/news/covid-19triggered-unprecedented-collaboration-research
[https://perma.cc/HFN3-CDKS]
(summarizing the findings from a January 2021 report on Science and Technology by the
Organisation for Economic Co-Operation and Development (OECD) that the pandemic has
“further opened access to data and publications, increased the use of digital tools, enhanced
international collaboration, spurred a variety of public-private partnerships, and encouraged
the active engagement of new players”).
44
See, e.g., Eskild Petersen, Marion Koopmans, Unyeong Go, Davidson H. Hamer,
Nicola Petrosillo, Francesco Castelli, Merete Storgaard, Sulien Al Khalili & Lone Simonsen,
Personal View, Comparing SARS-CoV-2 with SARS-CoV and Influenza Pandemics, 20
LANCET INFECTIOUS DISEASES e238, e238 (Jul. 3, 2020), https://www.thelancet.com/journal
s/laninf/article/PIIS1473-3099(20)30484-9/fulltext
[https://perma.cc/5DFV-6QC7]
(discussing COVID-19’s death and transmission rates and effective strategies for combating
them).
45
E.g., Ian Le Guillou, COVID-19: How Unprecedented Data Sharing Has Led to
Faster-Than-Ever Outbreak Research, HORIZON (Mar. 23, 2020), https://horizonmagazine.eu/article/covid-19-how-unprecedented-data-sharing-has-led-faster-ever-out
break-research.html [https://perma.cc/3PK6-A2HU] (discussing some of these efforts).
42
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disease’s long-term prospects remain unanswered.46 The pandemic was thus
characterized by at least reasonably hoped-for temporal discreteness. That
discreteness seems to have contributed to the massive dedication of resources aimed
at eliminating the pandemic forever and as quickly as possible.47
C. Collective Nature and Consequences: Examples from COVID-19
One obvious example of both the collectiveness and severity principles
motivating innovation is that many have deemed the consequences of not addressing
the COVID-19 pandemic significant enough to undertake remarkable amounts of
collective innovation to address the disease. These efforts include scientists,
pharmaceutical companies, and governments around the world working together to
develop, at a record pace, vaccines and other treatments for the disease.48
In particular, the widespread and shared nature of the COVID-19 pandemic—
one would be hard-pressed to find an individual who has not been impacted by it in
some way—can help explain why society has seen unprecedented amounts of
collaboration and sharing of data by scientists in response.49 Shared adversity
increases cooperation,50 and collaboration and data sharing are cooperative
behaviors that do not always spontaneously occur in scientific and research settings.
Indeed, a number of researchers have remarked on the surprising and unprecedented
nature of the current levels of sharing and collaboration now taking place in COVIDrelated research.51
46
Michael Greshko, COVID-19 Will Likely Be with Us Forever. Here’s How We’ll Live
with It, NAT’L GEOGRAPHIC (Jan. 22, 2021), https://www.nationalgeographic.com/science
/2021/01/covid-19-will-likely-be-with-us-forever-heres-how-well-live-with-it/ [https://per
ma.cc/S6YA-XUWM] (suggesting that COVID-19 will never fully be eradicated, though
ending the pandemic phase of the disease looks promising).
47
See Jon Cohen, The $1 Billion Bet: Pharma Giant and U.S. Government Team Up in
All-Out Coronavirus Vaccine Push, SCIENCE (Mar. 31, 2020, 5:50 PM),
https://www.sciencemag.org/news/2020/03/1-billion-bet-pharma-giant-and-us-governmentteam-all-out-coronavirus-vaccine-push [https://perma.cc/6DZ4-BHDD] (discussing efforts
by the U.S. government and the pharmaceutical industry to develop effective vaccines).
48
The Coronavirus Vaccines Were Developed in Record Speed. Now, the Hard Part,
Editorial, N.Y. TIMES (Dec. 9, 2020), https://www.nytimes.com/2020/12/09/opinion/corona
virus-vaccine-distribution.html [https://perma.cc/2JUC-RMG2].
49
See, e.g., Naujokaitytė, supra note 43 (summarizing the findings from a January 2021
report on Science and Technology by the Organisation for Economic Co-Operation and
Development that the pandemic has led to “unprecedented global collaboration between
scientists”; for example, the report found that a quarter of all COVID-19-related academic
articles with a U.S. or Chinese co-author were co-authored with researchers from other
countries, and that more than three quarters of COVID-19-related articles were published as
open access, making them “freely available to other researchers”).
50
See, e.g., Sun, supra note 12, at 1138.
51
For a sense of the striking and unusual nature of the current level of academic sharing,
see, e.g., Alvin Powell, How Far Are We from a Vaccine? Depends on Who ‘We’ Is, HARV.
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Another clear example in the COVID-19 context of shared, consequential
adversity increasing cooperation comes in the form of legal innovation. Jorge
Contreras, Mark Lemley, and others created several legal instruments meant to
enable parties to effectively donate their intellectual property rights to the fight
against COVID-19.52 Those that make the so-called Open COVID Pledge commit,
depending on the license terms they sign up for, to forego enforcing certain of their
intellectual property rights against those making use of those rights to diagnose,
prevent, contain, or treat COVID-19.53 This is no small matter. Intellectual property
rights are often quite valuable, and companies are frequently quite protective of them
for that and other reasons.54 Despite that reality, many parties with highly valuable
intellectual property portfolios have taken some form of the Open COVID Pledge,
all in hopes of helping address the significant consequences that failing to address
the shared adversity of COVID-19 would entail.55
The perceived severe consequences of inaction have also spurred massive
investment by governments into the search for a solution to the pandemic. A report
by the Organisation for Economic Co-Operation and Development (OECD), for
example, found that national research funding organizations in countries for which
data was available collectively spent about five billion dollars on COVID-19-related
research funding in the first few months of the pandemic alone.56
GAZETTE (May 7, 2020), https://news.harvard.edu/gazette/story/2020/05/assessing-wherevaccine-efforts-stand-and-the-challenges-ahead/ [https://perma.cc/CJ8H-ZB2V] (quoting
Harvard public health research professor and former dean of the Harvard T. H. Chan School
of Public Health Barry Bloom as saying that he has “not seen anything like [the current level
of sharing] in my entire career”); Matt Apuzzo & David D. Kirkpatrick, COVID-19 Changed
How the World Does Science, Together, N.Y. TIMES (Apr. 14, 2020),
https://www.nytimes.com/2020/04/01/world/europe/coronavirus-science-research-cooperat
ion.html [https://perma.cc/H9ZV-4C6Y] (“While political leaders have locked their borders,
scientists have been shattering theirs, creating a global collaboration unlike any in history.
Never before, researchers say, have so many experts in so many countries focused
simultaneously on a single topic and with such urgency.”).
52
About Us, Open COVID Pledge, https://opencovidpledge.org/about/
[https://perma.cc/UL4L-V5TT] (last visited Mar. 31, 2021); Matthew Bultman, Scientists,
Lawyers, Create Coronavirus IP Pledge, BLOOMBERG LAW (Mar. 27, 2020, 3:52 PM),
https://news.bloomberglaw.com/ip-law/scientists-lawyers-create-coronavirus-ip-pledge
[https://perma.cc/L5RB-ZZTM] (detailing the effort by professors and others to create legal
instruments that enable parties to donate their intellectual property rights).
53
Bultman, supra note 52.
54
Randy Sabett, Protecting Your Company’s Intellectual Property, COOLEYGO,
https://www.cooleygo.com/protecting-your-intellectual-property/ [https://perma.cc/8RTRFXCH] (last visited Feb. 9, 2021) (detailing the value of intellectual property rights and ways
to protect them).
55
See, e.g., Jorge Contreras, Top Patent Holders Make Open COVID Pledge, OPEN
COVID PLEDGE (May 25, 2020), https://opencovidpledge.org/2020/05/25/top-patentholders-make-open-covid-pledge/ [https://perma.cc/YCZ4-FJCE] (detailing some of the
large companies that have dedicated their valuable intellectual property rights to the fight
against COVID-19).
56
Naujokaitytė, supra note 43.
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Of course, on the flip side, a sizeable number of people have deemed that the
severity of the pandemic is overblown57 and that vaccines and other treatments are
wasteful and even harmful in light of other pressing needs.58 For instance, some have
argued that COVID-19 poses minimal risk of death or other serious consequences
for most of the population, and so society should simply let the disease run its course
without completely disrupting day-to-day life.59 Other countries, including Sweden,
have at least partially followed this course.60 Others believe that the vaccines are
unsafe or are part of a conspiracy to track or otherwise harm people.61
This divide underscores an important point: even when adversity is collectively
experienced, not all parties experiencing the adversity will share the same views
about the consequences of leaving the adversity unaddressed. Some may not even
recognize the adversity as reality. But to the extent that a majority view develops,
that majority is likely to dictate society’s collective response, even if the minority
position affects or hinders the majority’s innovative solutions to the problem. For
instance, the vaccines developed in response to the COVID-19 pandemic may fall
short of their potential when many people choose not to be vaccinated, even if they
help address the disease for many.62
57

Amna Nawaz, Why Do Some Americans Feel Pandemic Fears Are Overblown?, PBS
NEWSHOUR (Oct. 6, 2020, 6:50 PM EST), https://www.pbs.org/newshour/show/why-dosome-americans-feel-pandemic-fears-are-overblown [https://perma.cc/8GL9-5BGE].
58
10 Myths About the COVID-19 Vaccine that Aren’t True, HENRY FORD HEALTH SYS.
BLOG (Dec. 21, 2020), https://www.henryford.com/blog/2020/12/vaccine-myths
[https://perma.cc/659G-7WYP] (discussing opposition to the vaccine and why the concerns
are not merited).
59
See, e.g., Joshua Cohen, The Trump Administration Goes All In on Herd Immunity,
FORBES (Oct. 10, 2020, 8:43 AM EDT), https://www.forbes.com/sites/joshuacohen/2020/
10/10/where-does-the-trump-administration-stand-on-herd-immunity/?sh=7a48324572f5
[https://perma.cc/N9B9-KRGU] (detailing the Trump Administration’s promotion of
pursuing herd immunity rather than implementing strict isolation policies).
60
Misha Gajewski, Stop Trying to Make ‘Herd Immunity’ Happen: Sweden’s Attempt
at COVID-19 Herd Immunity Failed, FORBES (Aug. 11, 2020, 7:20 PM EDT),
https://www.forbes.com/sites/mishagajewski/2020/08/11/stop-trying-to-make-herd-immun
ity-happen-swedens-attempt-at-covid-19-herd-immunity-failed/?sh=3cf32fb541cb
[https://perma.cc/3A9N-773J] (discussing this effort and explaining that Sweden
implemented herd immunity and has had “higher rates of viral infection, hospitalisation and
mortality compared with neighbouring countries”).
61
Jack Goodman & Flora Carmichael, Coronavirus: Bill Gates ‘Microchip’
Conspiracy Theory and Other Vaccine Claims Fact-Checked, BBC (May 29, 2020),
https://www.bbc.com/news/52847648 [https://perma.cc/FUH9-4JQ9] (discussing a
conspiracy theory that “the coronavirus pandemic is a cover for a plan to implant trackable
microchips and that the Microsoft co-founder Bill Gates is behind it”).
62
See, e.g., Philip Elliot, Science Delivers the COVID-19 Vaccine. Too Bad Not Enough
People Want It, TIME (Dec. 4, 2020, 2:45 PM EST), https://time.com/5918040/coronavirusvaccine-hesitancy/ [https://perma.cc/MR6L-TSP8] (“Back in May, 27% of Americans
surveyed by Pew said they would either “probably” or “definitely” not get a COVID-19
vaccine when it comes online. By November, that number surged to 39%. Among the
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Another important example of the severity and commonality principles at play
concerns the long-term effects of COVID-19 and so-called “long haulers.” As
briefly discussed above, long haulers are people who have been infected with
COVID-19 and continue to suffer the disease’s effects months (and perhaps even
years) after the initial infection.63 Scientists and others have begun to monitor and
study people suffering in this way and have also begun to study and speculate about
the possible long-term effects for anyone that has been infected with COVID-19.64
To the extent that serious long-term effects are shown to result in significant
numbers of COVID-19 sufferers, it becomes more likely that society will respond to
these realities with innovation because of the collective, serious nature of the
ongoing adversity.
On the other hand, assuming that most people infected with COVID-19 fully
recover and show no significant long-term effects, the small group of long haulers
may be left in the dark. And this may be so in part because the adversity does not
pose significant enough repercussions for enough people.65 Consistent with the
principles discussed above, innovation to address the problems faced by this
minority thus becomes less likely, even if that outcome is unjust.
II. POLICY IMPLICATIONS
The COVID-19 pandemic and its role in both stimulating and hindering
innovation has several important policy implications. In this Part, we briefly review
some of the more important ones.
A. In the Face of Adversity: When Intellectual Property Rights May Be
Unnecessary or Counterproductive
Predominant theories behind intellectual property laws, including patent,
copyright, and trade secret laws, view each of these bodies of law—to varying
degrees—as necessary to incentivize parties to undertake socially beneficial
diehards who said they definitely would not participate in a vaccination regime, the number
climbed from 11% to 18%.”).
63
See supra notes 31–36 and accompanying text; Anthony Komaroff, The Tragedy of
the Post-COVID “Long Haulers,” HARV. HEALTH BLOG (Oct. 15, 2020, 2:30 PM),
https://www.health.harvard.edu/blog/the-tragedy-of-the-post-covid-long-haulers-2020101
521173 [https://perma.cc/LB5Q-8TEQ].
64
See Francis Collins, Trying to Make Sense of Long COVID Syndrome, NIH
DIRECTOR’S BLOG (Jan. 19, 2021), https://directorsblog.nih.gov/2021/01/19/trying-to-makesense-of-long-covid-syndrome/ [https://perma.cc/84SX-PAPG] (finding that out of the
“3,762 individuals who responded to the survey . . . 2,464 respondents reported COVID-19
symptoms lasting six months or longer”).
65
Some long haulers, in fact, already worry about this very dynamic playing out. Matt
Reynolds, COVID-19 Long-Haulers Want You to Know That They’re Still Not Okay, WIRED
(Jan. 18, 2021), https://www.wired.co.uk/article/covid-19-long-haulers [https://perma.cc/JU
F6-FGR7].

2021]

COVID-19 AND ITS IMPACT(S) ON INNOVATION

819

activities.66 The thinking goes something like this: without rights in their intellectual
creations, parties will be loath to create them in the first place because others can so
readily replicate them at little or no cost. Intellectual property rights purportedly save
the day by enabling developers of intellectual goods to prevent such low-cost
copying. That ability, in turn, enables creators to recoup their costs of development
and thus provides them with incentives to create.67
Yet the COVID-19 pandemic in particular, and the relationship of adversity to
innovation more generally, suggests that adversity often stimulates innovation
without the need for intellectual property rights as incentives. For instance, as
discussed above, the shared adversity of the COVID-19 pandemic has led
researchers the world over to widely share their research findings in hopes of helping
address the global pandemic.68 In such instances of widespread sharing, scientists
have often eschewed credit or rights talk and instead focused on working toward
solutions to the pandemic; intellectual property rights seem to be the last thing on
their minds.69 Others have sprung to action to develop solutions to pandemic-related
problems, including, early on, a shortage of ventilators and other breathing
equipment.70 Furthermore, as discussed above, in many cases, parties have actually
donated their intellectual property rights to the fight against COVID-19.71 In all of
these and many other cases, intellectual property rights do not appear to motivate
the action. Rather, the shared adversity does.
This identification of adversity as a stimulator of innovation adds to an already
rich literature highlighting significant areas of innovation that either lack formal

66
See Clark D. Asay, Artificial Stupidity, 61 WM. & MARY L. REV. 1187, 1198–1225
(2020) (reviewing these theories).
67
Elizabeth L. Rosenblatt, A Theory of IP’s Negative Space, 34 COLUM. J.L. & ARTS
317, 318 (2011) (“American intellectual property law is grounded in incentive theory.”).
68
Apuzzo & Kirkpatrick, supra note 51 (discussing how scientists all over the world
have engaged in unprecedented levels of sharing research results).
69
For a discussion of a successful effort to obtain pledges from intellectual property
owners to forego enforcing their intellectual property rights against those pursuing solutions
to the COVID-19 pandemic, see Jorge L. Contreras, Michael Eise, Arial Ganz, Mark Lemley,
Jenny Molloy, Diane M. Peters & Frank Tietze, Pledging Intellectual Property for COVID19, 38 NATURE BIOTECH. 1146 (2020), https://www.nature.com/articles/s41587-020-0682-1
[https://perma.cc/TYF3-Z6R9].
70
Cristian Fracassi & Alessandro Romaioli, Opinion, We Made Copies of Ventilator
Parts to Help Hospitals Fight Coronavirus, N.Y. TIMES (Mar. 22, 2020),
https://www.nytimes.com/2020/03/22/opinion/ventilators-coronavirus-italy.html [https://pe
rma.cc/VGL6-TVB8] (discussing the efforts of two Italian engineers to help fight
coronavirus by creating ventilators and other breathing aids).
71
Open COVID Pledge Rolled Out to Make Patents and Other IP Available for COVID19 Response, NAT’L L. REV. (Apr. 21, 2020), https://www.natlawreview.com/article/opencovid-pledge-rolled-out-to-make-patents-and-other-ip-available-covid-19 [https://perma.cc/
5XX3-EKGW] (reviewing key aspects of the Open COVID Pledge effort).
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intellectual property protections72 or otherwise do not appear to rely on them
heavily.73 We do not have space here to review this literature comprehensively. One
of its main takeaways, however, is that norms, rather than formal intellectual
property rights, are often a key driving force behind significant amounts of
innovation.74 For instance, in the world of stand-up comedy, comedians often rely
on norms rather than intellectual property rights to protect their joke innovations and
to encourage the creation of new jokes.75 Over the last several decades, in the
software world, norms of openness and sharing have often predominated over
concerns about intellectual property rights, even among fierce commercial
competitors.76 This norms-based mode of innovation holds true with respect to many
areas of adversity-inspired innovation, including specifically in the COVID-19
context: as discussed above, norms of sharing and mutual support in response to
adversity have contributed to a number of innovations meant to address the COVID19 pandemic, including with regards to vaccines and treatments.
This role of adversity in inspiring innovation may mean that, in such adverse
conditions, intellectual property rights are not only unnecessary, but harmful. For
instance, intellectual property rights are known to impose significant societal costs,
including limiting access to intellectual goods.77 These costs are necessary, the
theory goes, because of what we discussed above: we fear that many societal goods
will never be developed if their developers cannot recoup the costs of creation.78 Yet
as we have seen, in the context of COVID-19 and other adverse conditions, that
theory simply is not true, at least in its entirety. Parties have rushed to develop
vaccines and other solutions to COVID-19 problems, not necessarily because of the
promise of rights, but because of the hope of a pandemic-free future. Admittedly, it
is difficult to generalize this point too much because deciphering the motivations of
millions of heterogeneous people and organizations the world over is impossible.
But what seems absolutely clear is that, without the global pandemic, many, perhaps
most, of the innovations that we have seen developed would not have come about,
intellectual property rights notwithstanding.
72

See generally Kal Raustiala & Christopher Sprigman, The Piracy Paradox:
Innovation and Intellectual Property in Fashion Design, 92 VA. L. REV. 1687, 1764 (2006)
(discussing IP’s “negative spaces,” or areas of significant innovation where formal
intellectual property protections do not play a role).
73
See generally Dotan Oliar & Christopher Sprigman, There’s No Free Laugh
(Anymore): The Emergence of Intellectual Property Norms and the Transformation of StandUp Comedy, 94 VA. L. REV. 1787 (2008) (arguing that intellectual property law is an
ineffective means of promoting stand-up comedians’ creativity and that social norms provide
a substitute for such protections).
74
Id.
75
Id.
76
For a brief review of the open source software movement, see Clark D. Asay, A Case
for the Public Domain, 74 OHIO ST. L.J. 753 (2013).
77
Mark A. Lemley, Property, Intellectual Property, and Free Riding, 83 TEX. L. REV.
1031, 1059–65 (2005) (reviewing some of these costs).
78
Id. at 1060.
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This putative lack of necessity of intellectual property rights for innovation in
response to crisis becomes all the more troubling if the known social costs of
intellectual property rights limit the innovations’ impact in solving the very
problems brought on by that crisis. For instance, if vaccines developed in response
to COVID-19 are subject to patent rights, those patents can be wielded to raise the
price of those vaccines and thereby limit access to them.79 Therefore, the end result
may be that fewer people get vaccinated, and the pandemic-induced solution does
not solve the problem as thoroughly as it otherwise might. Other pandemic-induced
innovations may similarly fail to reach their potential in solving pandemic-induced
problems when proprietary rights get in the way. Indeed, even when parties pursue
an innovation for reasons having nothing to do with the promise of intellectual
property rights, the presence of those rights often distorts such parties’ motivations
later on, resulting in an assertion of rights that ultimately inhibit society’s access to
helpful innovations.80
Of course, the role of intellectual property rights can certainly be more nuanced
than meets the eye, even when adversity is the primary stimulant to some innovation.
For instance, though the current pandemic pushed a host of researchers and
companies to pursue safe and effective vaccines at record speeds, intellectual
property rights in the form of patents may still be vital to success on that front.81
After all, large pharmaceutical companies such as Pfizer still need the ability to
recoup some of their billions of dollars spent developing, manufacturing, and
distributing vaccine dosages the world over.82 Indeed, pharmaceutical companies are
the poster child for supporters of strong patent rights because, it is argued, these
companies would never invest the billions of dollars it takes to develop life-saving
products without patent protections in place.83 In other cases of adversity-inspired
innovation, too, it may be that intellectual property rights, by providing innovators
a means by which to recoup their costs of development and distribution, play an
important role in parties pursuing innovation meant to help solve adversity-induced
problems.84 Indeed, commentators have frequently argued that intellectual property
79
Aisling McMahon, How Patents Will Affect Pandemic Vaccines and Treatments,
RTE (July 3, 2020, 4:06 PM), https://www.rte.ie/brainstorm/2020/0702/1150969-patentscoronavirus-vaccines-medicine-ireland/ [https://perma.cc/M8C8-NX4D].
80
Clark D. Asay, Patent Schisms, 104 IOWA L. REV. 45 (2018) (discussing this
phenomenon in the patent context).
81
For an opinion along these lines, see Thomas Cueni, The Risk of Suspending Vaccine
Patent Rules, Opinion, N.Y. TIMES (Dec. 10, 2020), https://www.nytimes.com/2020/12/10/
opinion/coronavirus-vaccine-patents.html [https://perma.cc/8ZF6-CF7D].
82
See Henry Grabowski, Patents, Innovation and Access to New Pharmaceuticals, 5 J.
INT’L ECON L. 849, 852–53 (2002) (reviewing some of the literature claiming that patents
are particularly important in the pharmaceutical industry’s ability to recoup costs allowing
them to innovate, grow, and prosper).
83
Id. at 850–53.
84
Aude S. Peden & Antoinette F. Konski, Coronavirus Innovation Guideposts on the
Eve of the COVID-19 Pandemic, NAT’L L. REV. (July 30, 2020),
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rights, even when they are not crucial to incentivizing parties to create things, are
vital to incentivizing further development, distribution, and commercialization of
those creations.85 In the COVID-19 context, it may be the case that many parties
moved to action by the pandemic would be unable to continue pursuing their
innovations without intellectual property rights as a means of recouping their
investment and commercialization costs.
But, as others have long pointed out, in many cases, intellectual property rights
are not the only, or even the best, means by which to enable developers of intellectual
goods to recoup their costs of development and commercialization.86 Another option
is direct government funding, including government payments, grants, prizes, tax
breaks, and other types of subsidies.87 In fact, when what is needed to address a
problem is generally known, these types of funding mechanisms are often preferable
to intellectual property rights because development and distribution of the solution
can be more precise, whereas intellectual property rights and the market leave
solutions susceptible to market pressures and attendant distortions.88 We can see
these principles at play in the case of COVID-19, where one of the most needed
solutions is one or more effective vaccines. Governments have responded by directly
paying significant amounts for vaccine development and distribution, though more
may be needed.89
Intellectual property rights may be a particularly bad fit for COVID-19 vaccine
development and distribution for other reasons as well. First, patents typically take
years to obtain and enforce, whereas the timeline for developing and distributing

https://www.natlawreview.com/article/coronavirus-innovation-guideposts-eve-covid-19pandemic [https://perma.cc/Q75J-X28B] (highlighting the fact that patent applications
relating to coronaviruses skyrocketed once the COVID-19 outbreak occurred).
85
Edmund W. Kitch, The Nature and Function of the Patent System, 20 J.L. & ECON.
265, 267 (1977) (discussing prospect theory as it applies to the patent system and its effects
on innovation). See generally Ted Sichelman, Commercializing Patents, 62 STAN. L. REV.
341 (2010) (discussing commercialization and its significant importance within the patent
system); Jonathan M. Barnett, Copyright Without Creators, 9 REV. L. & ECON. 389 (2013)
(discussing the importance of copyright as a means of encouraging distribution and
commercialization of copyrighted works).
86
See generally Daniel J. Hemel & Lisa Larrimore Ouellette, Beyond the Patents–
Prizes Debate, 92 TEX. L. REV. 303 (2013) (discussing some of these alternatives such as
prizes, grants, and tax incentives and the rich existing literature about each).
87
Id.
88
Id. at 317–26 (comparing the use and applicability of patents, prizes, grants, and
R&D tax incentives in practice).
89
See, e.g., Karen Weintraub & Elizabeth Weise, Federal Spending on COVID-19
Vaccine Candidates Tops $9 Billion, Spread Among 7 Companies, USA TODAY (Aug. 10,
2020, 9:32 AM ET), https://www.usatoday.com/story/news/health/2020/08/08/fedsspending-more-than-9-billion-covid-19-vaccine-candidates/5575206002/ [https://perma.cc
/YT8W-EW7W] (detailing the significant amount of investment from the U.S. government
in vaccine development).
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COVID-19 vaccines has proven to be much shorter.90 Hence, direct government
action, rather than leaving matters to market forces, is perhaps the only real solution,
in part because solely relying on intellectual property rights for recoupment purposes
is simply too delayed and uncertain. Second, as Qiwei Claire Xue and Lisa
Larrimore Ouellette have argued, vaccines are generally subject to significant
underinvestment because they are not as profitable as repeat-purchase treatments.91
Because of this, significant amounts of direct government funding are likely
necessary to encourage the development of effective COVID-19 (and other)
vaccines, and we have seen this borne out by the involvement of governments the
world over in underwriting COVID-19 vaccine development and distribution. This
latter point also highlights the need for greater amounts of funding for basic research
to lay a scientific foundation for vaccines and other solutions that market forces may
otherwise leave underdeveloped. We take up this discussion further in the next
Section.
Of course, developers of such vaccines may still wish to patent the technologies
for future uses and profits; vaccine technologies developed during the COVID-19
pandemic, after all, may prove useful in future crises. In fact, the mRNA technology
behind several of the COVID-19 vaccines is the first successful application of that
technology as part of a vaccine, as much of it was developed and patented as part of
earlier research efforts.92 Furthermore, outside of the vaccine context, it is not
entirely clear what other specific innovations would be worthwhile and helpful in
responding to the pandemic. In such cases, leaving things to market forces rather
than direct government intervention may be the most prudent approach, though, as
discussed above, intellectual property rights are not the only means for incentivizing
private action. But for at least some parties, they may remain an important one.
B. Counteracting Harmful Path Dependencies by Funding Basic Research
While adverse conditions may stimulate innovation in the short term, leading
to the various implications for intellectual property policy discussed above, the longterm effects of the adversity on innovation pathways should not be overlooked. In
particular, innovation that arises in response to adversity will almost certainly lead
to path dependencies that impact future research efforts, for good or ill. While path
dependencies are not good or bad in and of themselves, and indeed may send society
down productive paths as well as addressing immediate adverse conditions, there is
a possibility that these path dependencies could lead to suboptimal innovation
outcomes in the long term and leave society vulnerable to future crises.
90
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91
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See Damian Garde, The Story of mRNA: How a Once-Dismissed Idea Became a
Leading Technology in the Covid Vaccine Race, STAT (Nov. 10, 2020),
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The idea behind path dependency is relatively intuitive. When parties focus
their efforts on specific products, knowledge, and routines, those efforts influence
future innovation choices.93 In a sense, parties become locked in by their previous
research efforts because it is more efficient and profitable to continue moving in the
same general direction while adopting the same general norms and approaches.94
These locked-in trajectories may present no problems for, and indeed may benefit,
future innovation. However, there is also a real possibility that they may lead to
suboptimal innovation outcomes because the innovation that takes place is not the
most socially beneficial,95 other important areas of research are left un- or underexplored,96 the approaches adopted are not the most efficient,97 or some combination
of all of these.
In the context of COVID-19, the potential long-term effects on future research
precipitated by the pandemic are already making themselves felt, with potential
positive and negative implications for innovation. On the positive side, there is
significant optimism that the pandemic has instigated lasting beneficial changes,
both in how researchers approach their work and how the resulting innovations reach
the public. For example, an OECD report on the effects of COVID-19 on academic
research notes that the pandemic has “further opened access to data and publications,
increased the use of digital tools, enhanced international collaboration, spurred a
variety of public-private partnerships, and encouraged the active engagement of new
players,” and predicts that these developments will lead to long-lasting changes and
speed a transition to a more open, collaborative global scientific community.98 As
one researcher approvingly noted, these changes are “pretty cool, right? You cut the
crap, for lack of a better word, and you get to be part of a global enterprise.”99
Furthermore, all the attention on vaccines in the short term may help address
the longstanding problem of underinvestment in vaccine technologies going
93
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forward. As discussed above, because vaccines are not as profitable as repeatpurchase items, they are sometimes neglected in research and development
efforts.100 However, the substantial investment in vaccine technologies spurred by
the pandemic may lead to extensions of those efforts in the future that significantly
benefit society.101
On the bureaucratic end of the equation, the comparatively nimble
governmental and regulatory responses to COVID-19 across the globe in facilitating
clinical trials and approving treatments have also been seen by many as the first step
toward a future where this efficiency is the norm rather than the exception.102 Of
course, the extent to which these promising developments will lead to true path
dependencies that change the way science is done and the resulting innovation is
disseminated remains to be seen. However, many policy analysts and scientists
believe that these changes are predictive of future trajectories rather than isolated
responses.103
We have seen similar innovations in the private sector, where many companies
have, out of necessity, become more efficient and nimbler or repurposed their
operations significantly in order to survive the pandemic’s lashings. For instance,
some predict that innovations in workspace arrangements, remote communications,
and delivery services that the pandemic spurred will outlast it and prove fruitful
going forward.104 Other companies have successfully pivoted their businesses to take
100
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advantage of and survive the pandemic’s economic tumult. In many cases, those
altered operations are helping ensure both short-term survival and long-term growth
opportunities.105 These positive innovations may spur further developments in these
and other areas, and those developments may very well continue to benefit society
going forward.
On the flip side, however, there is also a very real possibility that many of these
COVID-19-induced innovations will have negative long-term impacts on
innovation. One of these impacts may be a sustained overinvestment in biomedical
research, to the detriment of other crucial areas of interest. For example, a New York
Times article reports that currently, “[n]early all [non-COVID-related] research has
ground to a halt,” and that “[a]s a practical matter, medical scientists today have little
choice but to study the coronavirus if they want to work at all.”106 This is partly due
to lockdowns and work-from-home restrictions,107 but it is also due to a diversion of
research funding from other areas to COVID-related investigation.108 Indeed, a
recent survey of academic researchers published in a report by the Frontiers open
access publisher shows significant concern among academics outside the biomedical
community that there will be a sustained reduction in funds available to them due to
such diversions.109 That concern is not unfounded, as an OECD report on the effects
of COVID-19 on academic research suggests. The report warns that the widespread
engagement spurred by the pandemic “risks diverting research efforts
indiscriminately away from non-COVID-19-related topics.”110 As scientists and
laboratories reconfigure their priorities and research agendas to adjust to this new
funding reality, path dependencies may, in turn, lead to a sustained move towards
biomedical research and away from other areas of interest. Indeed, in the context of
vaccine technology, path dependencies may swing the pendulum from
underinvestment to significant overinvestment. While those investments may help
address serious diseases, the excess may leave other important areas of innovation
underexplored.
One crucial area of study that might suffer as a result of this potential shift is
the field of environmental science. In the Frontiers survey of academic researchers,
environmental and geological scientists expressed the greatest concern about losing
change-the-way-we-work [https://perma.cc/38AQ-TN8S] (last visited Feb. 9, 2021)
(discussing some of these dynamics).
105
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future funding opportunities due to the COVID-19 pandemic.111 This is significant
because of a consensus in the academic community that climate change is one of the
biggest threats facing society today, requiring an immediate and substantial response
from both scientists and governments if it is to be properly addressed.112 Indeed,
some scientists have drawn parallels between climate change and the COVID-19
pandemic, suggesting that a similar coordinated global response is necessary to
properly address the threats it poses,113 threats that include leaving society more
vulnerable to future pandemics.114 But if path dependencies arising from increased
investment in biomedical science lead to a subsequent dearth of resources for
developing solutions to climate change, society will very likely suffer as a result.
The private sector’s focus on innovation responsive to the pandemic may
similarly result in ongoing innovation efforts that leave crucial areas of innovation
underdeveloped. For instance, innovations in remote learning and communications
that the pandemic has inspired may become so entrenched that companies continue
iterating on those improvements while neglecting other innovation opportunities that
promise greater improvements in learning, communications, or otherwise. Similarly,
an overemphasis on improving and focusing on “last-mile” delivery services may
cause companies to neglect other areas of operations that could benefit from
innovative efforts.115 Again, while iterating on all these pandemic-induced
innovations may prove at some level fruitful, the focus on them may leave other
important areas of innovation unexplored.
How might policymakers address the potential negative consequences of path
dependencies resulting from the innovation community’s response to COVID-19
and other adverse events? One possible solution lies in increased investment in basic
research funding across a wide swath of fields.
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By maintaining a commitment to basic research across all fields, society avoids
the problem researchers are currently foreseeing, where resources become diverted
and monopolized by the needs of the moment, potentially leading, through path
dependencies, to long-lasting lacunae in other areas that leave society vulnerable to
future crises.
While some of these crises, like climate change, are foreseeable, many others
are not. Because basic research, by definition, is practiced with no practical ends in
mind,116 it is particularly suited to developing a body of knowledge that may help
prevent or mitigate a host of future unforeseen adverse events. Indeed, researchers
have pointed out how the impressively fast response to developing a COVID-19
vaccine was made possible only by years of basic research that laid the scientific
foundation for this endeavor.117
It is no surprise, then, that researchers surveyed about the effects of COVID-19
on their profession primarily called for increased investments in basic research.118
One surveyed researcher framed the path dependency problem and its solution in
this way: “The continuous reduction of regular funding to the basic sciences can be
[exacerbated] by reorienting funding to hot topics. The long-term solution is to
strengthen regular funding so that, if such crises arise again, the scientific
community is properly armed.”119
Even before the current pandemic, “hot-topic” research had become the norm,
not the exception. Indeed, responding to budget crunches, universities have
increased pressure on their faculty researchers to focus their efforts on research that
is more readily monetized, through patenting or the creation of commercial
enterprises.120 Our point is not that these types of endeavors lack merit or that
researchers should not focus their efforts on immediate problems as well. Instead, it
is simply to highlight the importance of basic research funding in preparing society
to tackle both known and unforeseeable obstacles.
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C. Reforming Bayh-Dole to Minimize Harmful Implications for Innovation
in Adversity
A discussion of intellectual property rights, basic research, and path
dependencies would be incomplete without considering how the Bayh-Dole Act
figures into the equation. Implemented in 1980, Bayh-Dole provides, among other
things, for the patenting of inventions arising from federally funded research.121 This
change was made in part because of concerns that the research being performed with
government money, primarily in university laboratories, was not being sufficiently
commercialized.122 Offering patent protection to inventions arising from this
research was thought to be a way to incentivize the creation and marketing of useful
inventions from the basic research being performed in federally funded university
labs.123
Forty years later, the implications of Bayh-Dole for innovation policy have
been widely debated.124 While many have praised the Act’s success in achieving its
stated goal of increasing commercialization of university research,125 others have
argued that Bayh-Dole has contributed to deadweight loss,126 interfered with
productive scientific norms,127 and stymied innovation by creating patent
anticommons in certain areas.128 For example, empirical work suggests that
academic sharing norms suffer when university researchers plan to patent their
findings, which they now increasingly do under Bayh-Dole.129 Arti Rai and Rebecca
121
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Eisenberg have argued that, in addition to spurring commercializable innovation,
Bayh-Dole has led to a counterproductive surge in patenting of basic research in
biotechnology, a properitization of the basic building blocks of science that risks
impeding the advance of science by creating an anticommons that raises transaction
costs and makes progress in the field more challenging.130
These potential unfortunate consequences of Bayh-Dole have implications for
innovation in times of adversity. First is the concern about anticommons. If the
increased patenting of basic research under Bayh-Dole does indeed lead to
anticommons problems, there is a real danger that researchers will be less nimble in
their ability to respond to various crises as they arise. Rather than focusing all of
their efforts on finding solutions to a problem, they will instead be required to spend
valuable time navigating the permissions necessary to do the work they would like
to do. They may also be dissuaded from pursuing particular research agendas
altogether.
The increased academic secrecy that has resulted from Bayh-Dole is also a
particular concern for innovation in adversity. If researchers seeking to find
solutions to adverse events do this work with an eye to patenting their findings,
which has increasingly become the norm under Bayh-Dole, they may be less willing
to share these findings with others. This is troubling because, as we have seen, the
sharing of research results has been a critical factor in the speed and success of the
scientific community’s search for solutions to the COVID pandemic. Of course, as
we discussed above, the pandemic likely spurred increased sharing behaviors, which
may mitigate this concern somewhat—perhaps adversity itself, when it arises, will
counter the detrimental secrecy norms triggered by Bayh-Dole. But the concern
remains that university researchers will still be less willing to share and collaborate
under Bayh-Dole than if they could not patent their findings.
Finally, there is another potential adverse effect of Bayh-Dole on research
norms and basic research beyond incentivizing university labs to patent their basic
research work (and to maintain secrecy while seeking to do so). Because of the
increased focus on patenting in academic settings that Bayh-Dole has set in motion
and university technology transfer offices have embraced and encouraged,131 the Act
may have initiated a shift in academic norms, however subtle, away from basic
research and towards research that has clear commercial or practical application and
is thus more easily patented.132 And due to path dependencies, this shift in norms
could lead to a long-term trend away from basic research and towards work that has
130

Rai & Eisenberg, supra note 128, at 291 (“Th[e] frenzy of proprietary claiming [of
basic research in biotechnology] . . . [p]aradoxically . . . in the long run . . . may hinder rather
than accelerate biomedical research.”).
131
For a discussion of the role university tech transfer offices have played in the
patenting of university research subsequent to Bayh-Dole, see Mark A. Lemley, Are
Universities Patent Trolls?, 18 FORDHAM INTELL. PROP. MEDIA & ENT. L.J. 611 (2008).
132
See, e.g., CONG. RSCH. SERV., RL32076, THE BAYH-DOLE ACT: SELECTED ISSUES
IN PATENT POLICY AND THE COMMERCIALIZATION OF TECHNOLOGY 13 (Dec. 3, 2012)
(stating a concern held by some experts that Bayh-Dole has led to “a greater emphasis on
applied rather than basic research”).

2021]

COVID-19 AND ITS IMPACT(S) ON INNOVATION

831

foreseeable applications. While that could be positive for responding to the
immediate adverse events that threaten society, like climate change, it also risks
leaving society vulnerable to future, unforeseen adverse events, events that, to be
dealt with efficiently, will likely require a foundation of basic research for which the
application is not yet clear.
These potential negative consequences of Bayh-Dole for responding to societal
adverse events do not necessarily lead us to conclude that the Act should be
jettisoned entirely. But they do offer an additional perspective on the costs and
benefits of allowing federally funded research to be patented. Other scholars have
proposed various reforms to the Bayh-Dole system that could alleviate some of these
concerns. For example, Arti Rai and Rebecca Eisenberg argue that the National
Institutes of Health should be given the power to prevent the patenting of some
federally funded inventions, with the caveat that this power be used only in
exceptional cases to prevent the patenting of the basic building blocks of science.133
Ian Ayres and Lisa Larrimore Ouellette have proposed implementing a market test
to determine whether a federally funded invention requires a patent to incentivize its
commercialization.134 The specific implications of Bayh-Dole for society’s ability
to respond nimbly and successfully to adversity strengthen the case for proposals
like these.
CONCLUSION
In this Article, we have highlighted several characteristics of adversity that tend
to promote innovation and others that often inhibit it. The basic takeaway is what
we might call a Goldilocks principle: adversity that is either too intense or too mild,
too fleeting or too enduring, too encompassing or too narrow, too severe or too
insignificant, or too commonly shared or too isolated, is less likely to inspire
innovation. Instead, adversity that is “just right,” or somewhere in the middle of
these extremes, stands the best chance of inspiring innovation, all else being equal.
We then applied those learnings to specific examples in the COVID-19 context,
illustrating instances of the pandemic both spurring and blocking innovative efforts.
That discussion has shed light on several possible policy implications. First,
applying intellectual property rights to adversity-inspired innovations, including
COVID-19 vaccines, may be unnecessary; and, worse, might actually stand in the
way of those innovations solving the problems they were designed to address. Direct
government funding is often a better route to helping fund adversity-inspired
innovators, particularly when the wanted solution is well understood, as others have
pointed out. Second, adversity-inspired innovation can result in path dependencies
that both benefit and harm society in the future, and we point to a greater
commitment to basic research funding as one means to help address those possible
future harms. Finally, we join a chorus of others who have advocated for a
reexamination of federal laws that allow for patenting of federally funded research.
133
134

Rai & Eisenberg, supra note 128, at 310.
Ayres & Ouellette, supra note 124, at 301–04.

832

UTAH LAW REVIEW

[NO. 4

We believe this reexamination is important in light of the role that intellectual
property rights may play in both inhibiting access to adversity-inspired innovations
and entrenching negative path dependencies in research pathways. In particular, the
focus on patenting federally funded research may frequently steer researchers away
from basic research and its solutions to unforeseen societal problems.

